Literature DB >> 22640817

PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool.

Joakim Nyberg1, Sebastian Ueckert, Eric A Strömberg, Stefanie Hennig, Mats O Karlsson, Andrew C Hooker.   

Abstract

Several developments have facilitated the practical application and increased the general use of optimal design for nonlinear mixed effects models. These developments include new methodology for utilizing advanced pharmacometric models, faster optimization algorithms and user friendly software tools. In this paper we present the extension of the optimal design software PopED, which incorporates many of these recent advances into an easily useable enhanced GUI. Furthermore, we present new solutions to problems related to the design of experiments such as: faster and more robust FIM calculations and optimizations, optimizing over cost/utility functions and diagnostic tools and plots to evaluate design performance. Examples for; (i) Group size optimization and efficiency translation, (ii) Cost/constraint optimization, (iii) Optimizations with different FIM approximations and (iv) optimization with parallel computing demonstrate the new features in PopED and underline the potential use of this tool when designing experiments.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Year:  2012        PMID: 22640817     DOI: 10.1016/j.cmpb.2012.05.005

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  26 in total

1.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

3.  Simultaneous optimal experimental design for in vitro binding parameter estimation.

Authors:  C Steven Ernest; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-13       Impact factor: 2.745

4.  Optimizing disease progression study designs for drug effect discrimination.

Authors:  Sebastian Ueckert; Stefanie Hennig; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-27       Impact factor: 2.745

5.  Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.

Authors:  Giulia Lestini; Cyrielle Dumont; France Mentré
Journal:  Pharm Res       Date:  2015-06-30       Impact factor: 4.200

6.  Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment.

Authors:  Matts Kågedal; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-03-20       Impact factor: 2.745

7.  Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models.

Authors:  Theodoros Papathanasiou; Anders Strathe; Rune Viig Overgaard; Trine Meldgaard Lund; Andrew C Hooker
Journal:  AAPS J       Date:  2019-07-29       Impact factor: 4.009

Review 8.  Opportunities for model-based precision dosing in the treatment of sickle cell anemia.

Authors:  Min Dong; Tomoyuki Mizuno; Alexander A Vinks
Journal:  Blood Cells Mol Dis       Date:  2017-08-09       Impact factor: 3.039

9.  Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Authors:  Chandrasekar Durairaj
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

10.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.